# BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
Canonical URL: https://biopharmsignal.com/news/BTAI/bioxcel-therapeutics-provides-business-update-and-reports-first-quarter-2026-financial-results
Ticker: BTAI
Company: BioXcel
Source: BioXcel
Published: 2026-05-15 11:00 EST
Original Source URL: https://ir.bioxceltherapeutics.com
## Summary

FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date  Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer’s dementia Evaluating strategic options with an advisor to maximize shareholder value and advance the

## Article Body
FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date  Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer’s dementia Evaluating strategic options with an advisor to maximize shareholder value and advance the
## Recent Company News
- 2026-05-28 11:00 EST — [BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting](https://biopharmsignal.com/news/BTAI/bioxcel-therapeutics-presents-new-data-from-serenity-at-home-phase-3-trial-for-agitation-associated-with-bipolar-disorders-or-schizophrenia-at-2026-ascp-annual-meeting) — Source: BioXcel
- 2026-05-15 11:00 EST — [BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/BTAI/bioxcel-therapeutics-provides-business-update-and-reports-first-quarter-2026-financial-results) — Source: BioXcel
- 2026-04-17 11:00 EST — [BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting](https://biopharmsignal.com/news/BTAI/bioxcel-therapeutics-announces-virtual-event-to-discuss-commercial-launch-plan-based-on-market-opportunity-assessment-for-igalmir-in-the-at-home-setting) — Source: BioXcel
- 2026-04-08 11:00 EST — [BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions](https://biopharmsignal.com/news/BTAI/bioxcel-therapeutics-announces-enrollment-of-first-patients-in-u-s-department-of-war-funded-study-of-bxcl501-sublingual-dexmedetomidine-for-treatment-of-acute-stress-reactions) — Source: BioXcel
- 2026-04-01 11:00 EST — [BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting](https://biopharmsignal.com/news/BTAI/bioxcel-therapeutics-announces-food-and-drug-administration-acceptance-of-supplemental-new-drug-application-for-use-of-igalmir-in-the-at-home-setting) — Source: BioXcel
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)